Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 9 | 2022 | 165 | 0.750 |
Why?
|
| Phenylurea Compounds | 4 | 2019 | 27 | 0.510 |
Why?
|
| Pyrimidines | 4 | 2019 | 120 | 0.510 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 637 | 0.490 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 2 | 2022 | 2 | 0.410 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2010 | 30 | 0.360 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2022 | 48 | 0.360 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 187 | 0.300 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2015 | 54 | 0.280 |
Why?
|
| Receptor, TIE-2 | 2 | 2017 | 7 | 0.280 |
Why?
|
| Disease Progression | 1 | 2010 | 1026 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 173 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 866 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 138 | 0.260 |
Why?
|
| ras Proteins | 2 | 2015 | 77 | 0.250 |
Why?
|
| Multiple Sclerosis | 2 | 2007 | 203 | 0.240 |
Why?
|
| Macrophages | 2 | 2021 | 992 | 0.230 |
Why?
|
| Pyrazoles | 2 | 2017 | 71 | 0.220 |
Why?
|
| Urea | 1 | 2022 | 32 | 0.210 |
Why?
|
| Population Surveillance | 1 | 2003 | 208 | 0.200 |
Why?
|
| Cell Line, Tumor | 8 | 2019 | 1347 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 17 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 32 | 0.160 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 141 | 0.150 |
Why?
|
| Neoplasms | 2 | 2019 | 1226 | 0.150 |
Why?
|
| Quinolines | 1 | 2017 | 37 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 27 | 0.140 |
Why?
|
| Pyridines | 1 | 2017 | 96 | 0.140 |
Why?
|
| Structure-Activity Relationship | 5 | 2022 | 371 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 4 | 0.130 |
Why?
|
| Anilides | 1 | 2015 | 15 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2015 | 22 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2015 | 192 | 0.120 |
Why?
|
| Mice, Nude | 3 | 2021 | 256 | 0.120 |
Why?
|
| Mutation | 4 | 2019 | 2411 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 375 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2021 | 932 | 0.100 |
Why?
|
| Humans | 16 | 2022 | 58877 | 0.100 |
Why?
|
| Drug Design | 3 | 2022 | 143 | 0.100 |
Why?
|
| Amides | 2 | 2012 | 50 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 6 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2011 | 32 | 0.090 |
Why?
|
| Natalizumab | 1 | 2010 | 10 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 112 | 0.090 |
Why?
|
| Optical Fibers | 1 | 2010 | 8 | 0.090 |
Why?
|
| Mice | 7 | 2021 | 10139 | 0.090 |
Why?
|
| Laryngoscopes | 1 | 2010 | 22 | 0.090 |
Why?
|
| Trachea | 1 | 2010 | 90 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 572 | 0.080 |
Why?
|
| Female | 8 | 2021 | 30603 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 220 | 0.080 |
Why?
|
| Analgesia | 1 | 2009 | 31 | 0.080 |
Why?
|
| Male | 8 | 2021 | 27270 | 0.080 |
Why?
|
| Anesthesia | 1 | 2009 | 50 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 285 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1138 | 0.080 |
Why?
|
| Bariatric Surgery | 1 | 2009 | 44 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2009 | 76 | 0.080 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Pain, Postoperative | 1 | 2009 | 126 | 0.070 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2007 | 15 | 0.070 |
Why?
|
| Self Administration | 1 | 2007 | 45 | 0.070 |
Why?
|
| Aniline Compounds | 1 | 2007 | 27 | 0.070 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 69 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2021 | 1108 | 0.070 |
Why?
|
| Animals | 8 | 2021 | 19399 | 0.070 |
Why?
|
| Pyridones | 1 | 2007 | 35 | 0.070 |
Why?
|
| Interferon-beta | 1 | 2007 | 76 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 560 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 228 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 146 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2015 | 7 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 370 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2015 | 857 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 174 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 879 | 0.060 |
Why?
|
| North Carolina | 1 | 2003 | 65 | 0.060 |
Why?
|
| DCC Receptor | 1 | 2022 | 2 | 0.050 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2022 | 9 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 13 | 0.050 |
Why?
|
| Rats | 2 | 2021 | 1890 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 15596 | 0.050 |
Why?
|
| Middle Aged | 4 | 2021 | 16199 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 214 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2026 | 0.050 |
Why?
|
| Young Adult | 2 | 2021 | 4264 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2019 | 49 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 102 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 194 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 31 | 0.040 |
Why?
|
| CHO Cells | 1 | 2019 | 191 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1438 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2019 | 501 | 0.040 |
Why?
|
| Angiopoietins | 1 | 2017 | 5 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 509 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2017 | 2855 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 458 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2015 | 13 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 90 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 12 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 56 | 0.030 |
Why?
|
| Dimerization | 1 | 2015 | 145 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 42 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 70 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2015 | 65 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2010 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 119 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 201 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 187 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 430 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 201 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 305 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 418 | 0.030 |
Why?
|
| Monocytes | 1 | 2015 | 349 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 687 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2012 | 317 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2003 | 6006 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 68 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 5079 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 546 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 415 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 524 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2009 | 114 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 727 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 757 | 0.020 |
Why?
|
| Clinical Nursing Research | 1 | 2007 | 2 | 0.020 |
Why?
|
| Interferon beta-1b | 1 | 2007 | 5 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2007 | 18 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 53 | 0.020 |
Why?
|
| Air | 1 | 2007 | 16 | 0.020 |
Why?
|
| Erythema | 1 | 2007 | 11 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 867 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 447 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2007 | 40 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 52 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 83 | 0.020 |
Why?
|
| Benzamides | 1 | 2007 | 51 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 157 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 70 | 0.020 |
Why?
|
| Nurse's Role | 1 | 2007 | 121 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2007 | 134 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1536 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 445 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 13293 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2556 | 0.010 |
Why?
|